1. Home
  2. AXGN vs AGEN Comparison

AXGN vs AGEN Comparison

Compare AXGN & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Axogen Inc.

AXGN

Axogen Inc.

N/A

Current Price

$31.16

Market Cap

1.4B

Sector

Health Care

ML Signal

N/A

Logo Agenus Inc.

AGEN

Agenus Inc.

N/A

Current Price

$3.64

Market Cap

126.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AXGN
AGEN
Founded
N/A
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
126.2M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
AXGN
AGEN
Price
$31.16
$3.64
Analyst Decision
Strong Buy
Buy
Analyst Count
9
2
Target Price
$33.67
$14.50
AVG Volume (30 Days)
1.1M
454.3K
Earning Date
10-29-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$214,709,000.00
$106,829,000.00
Revenue This Year
$21.57
$67.15
Revenue Next Year
$15.79
N/A
P/E Ratio
N/A
N/A
Revenue Growth
18.72
N/A
52 Week Low
$9.22
$1.38
52 Week High
$34.24
$7.34

Technical Indicators

Market Signals
Indicator
AXGN
AGEN
Relative Strength Index (RSI) 64.72 34.22
Support Level $28.98 $3.82
Resistance Level $30.76 $4.12
Average True Range (ATR) 1.64 0.19
MACD -0.28 -0.06
Stochastic Oscillator 56.21 0.23

Price Performance

Historical Comparison
AXGN
AGEN

About AXGN Axogen Inc.

Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.

About AGEN Agenus Inc.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Share on Social Networks: